Also Known As: Dexlansoprazole, Dexilant, Kapidex
Dexlansoprazole (INN, trade names Kapidex, Dexilant) is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer of lansoprazole. The compound was launched in the US for use in the treatment and maintenance of patients with erosiveoesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD). Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009.
After racemic lansoprazole is applied orally, 80% of the circulating drug is dexlansoprazole. Moreover, both enantiomers have a similar effect on the proton pump. Consequently, the main advantage of Kapidex is not the enantiopure substance, but the pharmaceutical formulation.
Kapidex is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later. As of November 2009, clinical relevance of this form of release has yet to be shown.
Dexlansoprazole selectively inhibits the parietal cell membrane enzyme (H+,K+)-ATPase, typically referred to as the proton pump, thus blocking the final step of acid production.